Annual zoledronic acid may be sufficient to prevent bone loss induced by gonadotrophin-releasing hormone agonist treatment in men with prostatic cancer

By  

Inpharma, Vol. 1, Iss. 1581, 2007-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Preoperative reduction of uterine fibroids in only 16 days by administration of a gonadotrophin-releasing hormone antagonist (Cetrotide)

By Felberbaum RE   Küpker W   Krapp M   Gehl B   Ludwig M   Diedrich K  

Reproductive BioMedicine Online, Vol. 3, Iss. 1, 2001-07 ,pp. : 14-18

Reproductive Healthcare Ltd

Access to resources Recommend Favorite

Luteinising hormone releasing hormone analogues in the treatment of prostate cancer

By Gommersall Lyndon M   Hayne Dickon   Shergill Iqbal S   Arya Manit   Wallace DMA  

Expert Opinion on Pharmacotherapy, Vol. 3, Iss. 12, 2002-12 ,pp. : 1685-1692

Informa Healthcare

Access to resources Recommend Favorite

Biochemical and functional aspects of gonadotrophin-releasing hormone and gonadotrophins

By Ulloa-Aguirre Alfredo   Timossi Carlos  

Reproductive BioMedicine Online, Vol. 1, Iss. 2, 2000-10 ,pp. : 48-62

Reproductive Healthcare Ltd

Access to resources Recommend Favorite

Gonadotrophin-releasing hormone antagonists: will they replace the agonists?

By Felberbaum Ricardo E   Diedrich Klaus  

Reproductive BioMedicine Online, Vol. 6, Iss. 1, 2003-01 ,pp. : 43-53

Reproductive Healthcare Ltd

Access to resources Recommend Favorite